Koers Signal Genetics Inc Nasdaq
Aandelen
US8266401046
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
09/05 | VIRIDIAN THERAPEUTICS, INC. : Oppenheimer herhaalt koopadvies | ZM |
09/05 | VIRIDIAN THERAPEUTICS, INC. : B. Riley haalt aandeel van kooplijst | ZM |
Omzet 2024 * | 235K 218K | Omzet 2025 * | 330K 306K | Marktkapitalisatie | 887 mln. 824 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -226 mln. -210 mln. | Nettowinst (verlies) 2025 * | -266 mln. -247 mln. | EV/omzet 2024 * | 1.811 x |
Nettoliquiditeiten 2024 * | 462 mln. 429 mln. | Nettoliquiditeiten 2025 * | 625 mln. 581 mln. | EV/omzet 2025 * | 794 x |
K/w-verhouding 2024 * |
-3,8
x | K/w-verhouding 2025 * |
-3,54
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 93,69% |
Recentste transcriptie over Signal Genetics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30-10-23 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 01-05-23 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-01-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 03-01-18 |
Tomas Kiselak
CHM | Chairman | 38 | 28-10-20 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30-10-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |
- Beurs
- Aandelen
- Koers VRDN
- Koers